Showing results (571-580 of 655) with videos related to

Sort By:
Pageof 66
Cardiovascular Diabetology|August 31, 2025
Left ventricular ejection fraction reserve and its association with myocardial perfusion, coronary calcification, and strain in type 2 diabetes without overt cardiovascular diseaseAdam Chebli, Ida K B Rasmussen, Anne-Cathrine Skriver-Møller, et al.
Diabetes Care|July 10, 2021
Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 DiabetesFarsad Afshinnia, Thekkelnaycke M Rajendiran, Chenchen He, et al.
Kidney International Reports|May 2, 2022
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic RegionsPriya Vart, Ricardo Correa-Rotter, Fan Fan Hou, et al.
Cardiovascular Diabetology|April 18, 2025
Sex differences in myocardial flow reserve among individuals with type 2 diabetes: insights from the DiaHeart studyAnne-Cathrine Skriver-Møller, Philip Hasbak, Ida K B Rasmussen, et al.
Pharmaceuticals (Basel, Switzerland)|September 28, 2023
Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept StudyMayra Alejandra Jaimes Campos, Iván Andújar, Felix Keller, et al.
Diabetologia|December 6, 2014
SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetesMarine Germain, Marcus G Pezzolesi, Niina Sandholm, et al.
Diabetes Research and Clinical Practice|October 20, 2022
Baseline risk markers and visit-to-visit variability in relation to kidney outcomes - A post-hoc analysis of the PERL studyViktor Rotbain Curovic, Neil Roy, Tine W Hansen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 12, 2024
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K Judge, Katherine R Tuttle, Natalie Staplin, et al.
The New England Journal of Medicine|March 4, 2026
Finerenone in Type 1 Diabetes and Chronic Kidney DiseaseHiddo J L Heerspink, Andreas L Birkenfeld, David Z I Cherney, et al.
Diabetes, Obesity & Metabolism|February 16, 2021
Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trialJoseph G Timmons, Nicola Greenlaw, James G Boyle, et al.
Pageof 66